Contact |
General |
Specializations in Countries |
Contribution to the Global Plan |
Declaration |
View this partner's profile
Organization Contact Information |
Name: |
Global Sustainable Development Program |
Street 1: |
P.O.Box KB926, Korlebu, Accra. |
Street 2: |
Ablekuma Borkorborkor Scania street |
City: |
Accra |
Province: |
Greater Accra |
Post Code: |
233 |
Country: |
Ghana |
Phone: |
0201806634 or 0275796545 |
Organization Email: |
dobia1958@yahoo.co.uk |
Web Site: |
http://www.ghsmail.org |
Other Online Presence: |
https://stoptb.org/partners |
Focal Point Contact Information |
Salutation: |
Mr. |
First Name: |
Ahamed |
Last Name: |
Iddrisu |
Title: |
ChiefTechnical Officer, Disease Control. |
Email: |
dobia1958@yahoo.co.uk |
Phone: |
233 275796545 |
|
Alternate Focal Point Contact Information |
Salutation: |
Mrs. |
First Name: |
Hamidatu |
Last Name: |
Iddrisu |
Title: |
Business Woman. |
Email: |
dobia1958@yahoo.co.uk |
Phone: |
0244077911 |
|
General Information |
Board Constituency: |
Countries |
Is your organization legally registered in your country: |
Yes |
If yes, please enter your registration number: |
CGO51302016 |
Organization Type - Primary: |
Non-Governmental Organization |
Organization Type - Secondary: |
Other Non-Governmental Organization (NGO) |
Organization Description: |
Global Sustainable Development Program: 1.Creating an enabling environment for community engagement a mutually enabling political, legal and policy environment based on the principles of equity, equality and mutual respect to increase the engagement of NGOs and other CSOs in TB activities . 2.challenges posed by major epidemics such as HIV/AIDS, TB, COVID-19 and malaria, and help individuals and families to cope with them, have certainly contributed to make people and health policy-makers more aware of the essential and complementary role of communities in ensuring high-quality patient care.3.TB/HIV elimination :Assisting early case finding, Assisting contact investigation, Providing treatment support, Preventing the transmission of drug-resistant TB and others. |
|
Do you know about the UNHLM declaration: |
Yes |
Specializations / Areas of Work |
Advocacy Civil Society and Community Engagement Delivery of health services and care Engaging political leaders and ensuring inclusive leadership Funding, including innovative and optimized approach to funding TB Care Provision of drugs, diagnostics and commodities Research and Development Technical Assistance Working on Community, Rights and Gender (CRG) Working on Key Populations related to TB |
Other Organization Information |
Total number of staff in your organization: |
6 - 10 |
Number of full-time staff who are directly involved with TB: |
1 - 5 |
Number of part-time staff who are directly involved with TB: |
1 - 5 |
Number of volunteers who are directly involved with TB: |
100 + |
|
How did you hear about the Stop TB Partnership: |
Involvement in TB control provision |
If you were informed or referred by another partner of the Stop TB Partnership please tell us who: |
Email and adverstiment |
Why do you wish join the Stop TB Partnership: |
Involvement in Stop TB Working Groups |
|
Are you a member of a Stop TB national partnership: |
Ghana |
Are you in contact with your national TB programme: |
Yes |
Please tell us how your organization is contributing to your country's national TB control plan: |
Advocacy communication and Social Mobilization. Contact tracing and investigation Monitoring and support visits. Training and workshops Implementation Research Continuous surveillance Policy Planning Monitoring and Evaluation |
|
Geographical Reach |
Which country is your headquarters located in: |
Ghana |
Which countries do you do operate in: (This includes countries you are conducting activities in) |
Ghana |
Contribution |
Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: |
TB Care Delivery: 1. Political commitment with increased and sustained financing Legislation, planning, human resources, management, Logistics information and Inventory Management systems ,training etc. 2. Surveillance:Case detection through quality-assured bacteriology Strengthening TB laboratories, drug resistance surveillance 3. Standardized treatment with supervision and patient support TB treatment and programme management guidelines, International Standards of TB Care (ISTC), PPM, Practical Approach to Lung Health (PAL), community-patient involvement 4. An effective drug supply and management system Availability of TB drugs, TB drug management, Global Drug Facility (GDF), Green Light Committee (GLC) 5. Monitoring and evaluation system and impact measurement TB recording and reporting systems, Global TB Control Report, data and country profiles, TB planning and budgeting tool, WHO epidemiology and surveillance online training
Drug-Resistant TB: Anti-tuberculosis (TB) drug resistance is a major public health problem that threatens progress made in TB care and control worldwide. Drug resistance arises due to improper use of antibiotics in chemotherapy of drug-susceptible TB patients. This improper use is a result of a number of actions including, administration of improper treatment regimens and failure to ensure that patients complete the whole course of treatment. Essentially, drug resistance arises in areas with weak TB control programmes. A patient who develops active disease with a drug-resistant TB strain can transmit this form of TB to other individuals. Pretomanid Tablet is an antimycobacterial indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug-resistant (XDR), treatment-intolerant or non-responsive multidrug-resistant (MDR) tuberculosis (TB).
TB-HIV: The risk of developing tuberculosis (TB) is estimated to be between 20-37 times greater in people living with HIV than among those without HIV infection. In 2010, there were 8.8 million new cases of TB, of which 1.1 million were among people living with HIV.
In response to demands from countries, WHO recommends 12 TB/HIV collaborative activities, including the Three I's for HIV/TB. The WHO HIV/AIDS and TB Departments and their partners, including community groups, work collaboratively on joint HIV/TB advocacy, policy development and implementation in countries. WHO also develops and promotes tools and guidelines to support countries in improving their TB/HIV collaborative action in order to achieve universal access to HIV and TB prevention, care and treatment services for all people in need. Strengthening Community Base TB/HIV Surveillance.
Laboratory Strengthening: I-TECH and GeneXpert Technology works, health needs and program goals are best met when local laboratories and service are reliable, consistent, and readily available. To deliver potentially life-saving results quickly and efficiently, laboratories must be well equipped and staffed with trained experts. Strengthened laboratories also have the capacity to share information with other laboratories worldwide, allowing them to become part of a global community and extending their resources. Current Laboratory Team activities include pre-service curriculum development; in-service training; support of ministries of health in strategic planning; implementation of laboratory information systems with I-TECH’s Informatics Team; and implementation of new laboratory technologies. As the team expands its scope, members will continue to prioritize these activities while responding to needs of partnering agencies as they arise. Logistics Information and Inventory Control Management systems.
New Diagnostics: The New Diagnostics Working Group is a one of the seven Working Groups of the Stop TB Partnership. It aiThe Xpert MTB/RIF – a rapid, fully-automated nucleic acid amplification test – first major breakthrough in tuberculosis diagnostics since sputum smear microscopy was developed more than 100 years ago.
New TB Drugs: The U.S. Food and Drug Administration approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs.14 Aug 2019.TB medicines bedaquiline and delamanid, the historical standard of care, still in use in much of the world, has approximately 60 percent treatment efficacy globally.
New TB Vaccines: Safe and effective tuberculosis (TB) vaccines are urgently needed. TB continues to take the lives of almost one and a half million people per year and devastates the lives of millions more. New TB vaccines are an urgent part of a comprehensive plan to control and ulimately eliminate TB. Over the past decade, researchers have made significant progress in TB vaccine development, and a dozen TB vaccine candidates are now being evaluated in clinical trials.Developing new TB vaccines is a costly, complex and time-consuming undertaking that requires a coordinated global effort. Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade provides a strategy to develop more effective TB vaccines as quickly and cost-effectively as possible. It was developed in consultation with stakeholders from the TB vaccine research community and outlines the major scientific challenges and priorities, critical activities and crucial questions that need to be addressed to develop these life-saving vaccines.
Fundamental Research: In contrast to profit-driven research, such as most applied research and development work,Fundamental research requires a special way of thinking that often combines seemingly unrelated facts and explores unknown fields necessary to make new discoveries. It is for this reason that cutting-edge, fundamental research is frequently multidisciplinary in nature. Standardised methods, techniques and procedures that were developed to solve relatrively clearly defined problems are generally not sufficient in fundamental research. A stroke of genius or an unconventional idea is usually needed to increase understanding of the environments, both natural and man-made, in which we live today. The talents necessary in fundamental research may be largely innate, but they do need a stable environment to develop. Encourage Implementation Research .
Research: Implementation research attempts to solve a wide range of implementation problems; it has its origins in several disciplines and research traditions.The strategy for combating TB and HIV with coordinated and integrated methods includes measures and resources to scale up participating countries' health-care systems, capacity building and drug and equipment procurement. In addition to specific project work, The Union achieves these objectives through:technical assistance (TA) missions through which HIV and TB/HIV experts provide support to national governments and ministries of health.Implementation research is an integrated concept that links research and practice to accelerate the development and delivery of public health approaches. Implementation research involves the creation and application of knowledge to improve the implementation of TB/HIV policies, programs, and integrated delivery systems and practices.
|
Declaration |
Declaration of interests:
Mobile workers and community base surveillance volunteers are usually in regular or constant transit. use to ensure patients complete treatment, cure, defaulter prevention and early detection of cases, In August, the Food and Drug Administration (FDA) announced its approval of pretomanid, a new drug developed to treat Extensively Drug-Resistant Tuberculosis (XDR-TB) and treatment intolerant/non-responsive Multidrug-Resistant (MDR) TB.4 Sept 2019 is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin),most powerful anti-tuberculosis drugs. Post-exposure prophylaxis (PEP): PEP refers to antiretroviral medicines that are taken after exposure or possible exposure to HIV. The exposure may be occupational, as in a needle stick injury, or non occupational, unprotected sex with a person living with HIV. Pre-exposure prophylaxis (PrEP): PrEP refers to antiretroviral medicines prescribed before possible exposure to HIV. We involve other NGOs and CSOs, integrate drug-resistant TB into their community-based work in many ways, without trained medical staff. It is important to do so when they are working with high-risk populations , people living with HIV, in congested environments (urban slums and prisons), drug users, sex workers and migrant workers. Assisting early case finding: Sputum examination, TB investigation in many settings. In community meetings (e.g. women's groups, clubs, social and health services integrated systems, farmers' groups etc.) People with symptoms helped to have their sputum examined by transporting either the person or the sputum sample to the nearest health facility. Contact investigation: Engaging members of the communities. Advocacy communication and social mobilization, Policy Planning Monitoring and evaluation. To achieve SDGs and 2030 Agenda provide an integrated roadmap for sustainable development.
|
Application date: |
October 15, 2012 |
Last updated: |
November 15, 2022 |
|